Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

On Wednesday, Novavax Inc. (NASDAQ:NVAX) reported second-quarter 2025 sales of $239.24 million, compared to $415 million a ...

Novavax (NVAX) Rises Higher Than Market: Key Facts July 14, 2025 — 05:45 pm EDT Written by Zacks Equity Research for Zacks -> ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

The NVAX vaccine was recently granted full approval by the FDA for use in older adults aged 65 and above, as well as use in individuals aged 12-64 years with at least one underlying condition that ...

Novavax (NASDAQ: NVAX) ended its seventh consecutive session in the red territory after shares of the company declined 1.35% to close at $6.56 on Friday. The vaccine maker lost close to 13% in the ...

Novavax Inc. (NASDAQ:NVAX) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 17, Citi initiated coverage of Novavax Inc.

Novavax Inc. closed 50.20% short of its 52-week high of $15.22, which the company reached on October 2nd.

In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.

Shares of Novavax Inc. NVAX slid 2.28% to $6.85 Wednesday, on what proved to be an all-around mixed trading session for the ...